【 Pharmaceutical Network Conference Forum 】Lung cancer is one of the malignant tumors with high incidence, and its clinical needs are huge and unmet. The 2024 European Conference on Lung Cancer (ELCC) was held in Prague, Czech Republic, from March 20 to 23 local time. The conference is a global academic event in the field of lung cancer, demonstrating innovative progress in the field of lung cancer, and exploring the future direction of treatment. In this meeting, the "Voice of China" cannot be ignored, including Hengrui and many other local pharmaceutical companies, as well as some domestic research institute teams, who released new research data results at the meeting. These breakthrough research is expected to bring more solutions to lung cancer diagnosis and treatment.
Among them, the long-term follow-up data update of Hengrui Medicine's innovative drug CARELIZAB combined with carboplatin and pemetrexed for first-line chemotherapy to drive gene negative advanced non-small cell lung cancer (NSCLC) (CameL study) appeared in ELCC.
The 5-year overall survival (OS) rate of advanced driver gene negative non-small cell lung cancer in the first-line treatment of carelizumab combined with chemotherapy was 31.2% (19.3% in the chemotherapy group), helping more patients to achieve long-term survival; The 4-year and 5-year progression free survival (PFS) rates were 16.1%, significantly controlling the disease progression of patients and reducing the risk of disease progression by 45%.
It is reported that the CameL sq study is a national multicenter, double-blind, randomized controlled phase III clinical study comparing the first-line treatment of stage IIIB to IV squamous non-small cell lung cancer (NSCLC) with CARELIZAB or placebo in combination with carboplatin and paclitaxel.
According to the data, Carelizumab is a humanized PD-1 monoclonal antibody independently developed by Hengrui Pharmaceutical and has intellectual property rights. At present, it has been approved for 8 indications among the five major tumor types of lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and lymphoma, and is a domestic PD-1 product with the highest number of approved indications and tumor coverage. According to the announcement of Hengrui Pharmaceutical, in 2020, the company purchased CARELIZAB for injection at 19800 yuan/bottle, and the actual purchase volume of medical institutions in the reporting period reached 31441 bottles.
A number of studies by the team of Guangdong Lung Cancer Research Institute were also included in the wall report of the conference, covering the fields of data update of clinical research, application research of biomarkers, innovation of AI assisted surgery technology, etc. Among them, Beamion Lung-1 is an ongoing Phase Ia/b trial. Phase Ia study aims to evaluate the efficacy of Zongertinib in HER2 abnormally positive solid tumors, and Phase Ib study aims to evaluate the efficacy of Zongertinib in HER2 mutation positive (HER2m+) non small cell lung cancer (NSCLC) (Phase Ib; NCT04886804) patients. The results showed that Zongertinib was well tolerated in HER2 TKD m+NSCLC patients and showed promising efficacy.
In addition, at the 2024 ELCC conference, there was also a study on the efficacy and safety of the first-line treatment of extensive small cell lung cancer (ES-SCLC) with the combination of arotinib/placebo and EC protocol (etoposide+carboplatin) from the Chinese team (ETER 701), who was invited to share the new research results in the form of Mini Oral at the conference. It is reported that the ETER701 study published the comparative data between the combination chemotherapy group and the simple chemotherapy control group: in the median follow-up time of 14 months, the mPFS of the combination chemotherapy group was 5.6 months (vs. 4.2 months for the chemotherapy group; HR, 0.44; 95% CI, 0.36 to 0.55; P<0.0001), the mOS was 13.3 months (vs. 11.9 months in the chemotherapy group, HR, 0.86; 95% Cl, 0.67-11.10; P=0.1723), and the incidence of adverse events above grade 3 was 94.3% vs.87.0%. In the first-line treatment of ES-SCLC, compared with chemotherapy alone, arotinib+chemotherapy can realize the dual benefits of PFS and OS. The treatment mode of anti angiogenesis+chemotherapy combined with chemotherapy and chemoimmunity has similar survival benefits, and the safety is controllable.
Disclaimer: In any case, the information or opinions expressed in this document do not constitute investment advice to anyone.
